Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study

被引:8
作者
Li, Xin [1 ]
Chen, Baohua [2 ]
An, Chao [1 ]
Cheng, Zhigang [1 ]
Han, Zhiyu [1 ]
Liu, Fangyi [1 ]
Yu, Jie [1 ]
Liang, Ping [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Ultrasound, 28 Fuxing Rd, Beijing 100853, Peoples R China
[2] 908th Hosp Chinese Peoples Liberat Army Joint Log, Dept Hepatobiliary Surg, Yingtan, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; microwave ablation; propensity score matching; transarterial chemoembolization; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; GUIDED RADIOFREQUENCY ABLATION; HEPATIC RESECTION; PLEURAL EFFUSION; LARGER; RISK;
D O I
10.4103/jcrt.JCRT_380_19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We aimed to compare the outcomes of microwave ablation (MWA) alone with those of transarterial chemoembolization combined with MWA (TACE-MWA) for Barcelona clinic liver cancer (BCLC) Stage B hepatocellular carcinoma (HCC) and to identify the prognostic factors associated with the two treatments. Materials and Methods: This retrospective study was conducted in 150 BCLC Stage B HCC patients from April 2006 to November 2017. Of these, 88 patients were treated with MWA alone while 62 with TACE-MWA. Propensity score matching (PSM) was conducted to adjust for imbalances in clinical parameters. Procedure-related complications, local tumor progression (LTP), recurrence-free survival (RFS), and overall survival (OS) were analyzed. Results: Before PSM, the maximal tumor diameters were 6.0 +/- 1.0 cm and 6.7 +/- 1.3 cm in the TACE-MWA and MWA groups, respectively, with a significant difference (P = 0.002); a significant difference was also detected in alpha-fetoprotein level (P = 0.013). After PSM, no difference was found in the two parameters (P = 0.067, 0.470). Before and after PSM, no difference was detected in the procedure-related complications (P = 0.803 vs. 1.000, P = 1.000 vs. 1.000), RFS (P = 0.786 vs. 0.689), and OS (P = 0.684 vs. 0.929). Tumor size and alpha-fetoprotein level were independent influencing factors for OS before and after PSM (P = 0.009, 0.023), while tumor size (D > 7) was an independent risk factor for poor OS (P = 0.011). Tumor number was an independent risk factor for RFS before and after PSM (P = 0.007 vs. P = 0.008). A significant difference was detected in LTP between the two groups with single tumor before and after PSM (P = 0.059 vs. P = 0.006). Conclusions: The MWA alone group had RFS and OS comparable to that of the TACE-MWA group. TACE-MWA was effective in controlling LTP in patients with a single tumor.
引用
收藏
页码:1027 / 1037
页数:11
相关论文
共 40 条
[1]  
Ahmed M, 2014, J VASC INTERV RADIOL, V25, P1706, DOI 10.1016/j.jvir.2014.09.005
[2]  
Ako S, 2018, ACTA MED OKAYAMA, V72, P47, DOI 10.18926/AMO/55662
[3]   Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study [J].
Biederman, Derek M. ;
Titano, Joseph J. ;
Bishay, Vivian L. ;
Durrani, Raisa J. ;
Dayan, Etan ;
Tabori, Nora ;
Patel, Rahul S. ;
Nowakowski, Francis S. ;
Fischman, Aaron M. ;
Kim, Edward .
RADIOLOGY, 2017, 283 (03) :894-904
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma [J].
Bruix, Jordi ;
Reig, Maria ;
Sherman, Morris .
GASTROENTEROLOGY, 2016, 150 (04) :835-853
[6]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[7]   Society of Interventional Radiology Clinical Practice Guidelines Introduction [J].
Cardella, John F. ;
Kundu, Sanjoy ;
Miller, Donald L. ;
Millward, Steven F. ;
Sacks, David .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2009, 20 (07) :S189-S191
[8]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[9]  
2-B
[10]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Reig, Maria ;
Bruix, Jordi .
LANCET, 2018, 391 (10127) :1301-1314